Search - tctmd.com

Displaying 181 - 200 of 224

Sort: Relevancy | Date

Presentation TCT 2014

TCT 614: Detailed Morphologic Characterization of the Strut Composition Following Absorb Scaffold Placement in a Porcine Coronary Artery Model Through 48 Months

Presenter: David P. Faxon, Fumiyuki Otsuka, MD

September 15, 2014

Presentation TCT 2014

Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect ABSORB

Presenter: Valentin Fuster, Patrick W. Serruys, Gregg W. Stone

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

ABSORB EXTEND: BVS Safe Out to 3 Years

September 14, 2014

Presentation TCT 2014

TCT 615: ABSORB EXTEND: An Interim Report on the 36-Month Clinical Outcomes from the First 250 Patients Enrolled

Presenter: Valentin Fuster, Pieter C. Smits

September 13, 2014

Presentation TCT 2013

Rationale for Bioresorbable Vascular Scaffolds as a VP Shield: The PROSPECT ABSORB Trial

Presenter: Gregg Stone

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

Bifurcation Strategies with the Absorb BVS Everolimus-Eluting Resorbable Scaffold: A Bench Study

Presenter: JM White

October 29, 2013

Presentation TCT 2013

TCT-36. One-year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis From the ABSORB Cohort B and the ABSO...

Presenter: Takashi Muramatsu

October 29, 2013

Presentation TCT 2013

TCT-34. The appearance of jailed side branches post-procedure, at 6, 12, 24 and 36 months following implantation of bioresorbable vascular devices – Insights from the ABSORB...

Presenter: Yoshinobu Onuma

October 29, 2013

Presentation TCT 2013

TCT-32. First Report of the Four Year Clinical Results of The ABSORB Trial Evaluating the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Patients...

Presenter: Bernard Chevalier

October 29, 2013

Presentation TCT 2013

TCT-31. ABSORB EXTEND: An Interim Report on the 24-month Clinical Outcomes from the First 250 Patients Enrolled

Presenter: Robert Whitbourn

October 29, 2013

Presentation TCT 2013

2 Cases: Absorb in a Distal Left Main Bifurcation and a Non Left Main Bifurcation

Presenter: Antonio Colombo

October 28, 2013

News Conference News TCT 2013

Bioresorbable Scaffold Stands Ground Next to Current DES

October 28, 2013

News Conference News TCT 2013

ABSORB III and IV Trials Aim to Prove Superiority of BVS

October 28, 2013

Presentation TCT 2013

Is ABSORB a Workhorse DES? Real-world Perspectives I

Presenter: Antonio Colombo

October 27, 2013

Presentation TCT 2013

The ABSORB III trial: Design, Goals and Enrollment Status

Presenter: Stephen Ellis

October 27, 2013

Presentation TCT 2013

Polylactic Acid Polymers: Chemistry and Structure in ABSORB 1.0 and 1.1

Presenter: Richard Rapoza

October 27, 2013

Presentation TCT 2013

Micro-CT Observations with ABSORB: Insights into Bifurcation Technique

Presenter: John Ormiston

October 27, 2013

Advertisement

TCT 614: Detailed Morphologic Characterization of the Strut Composition Following Absorb Scaffold Placement in a Porcine Coronary Artery Model Through 48 Months

Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect ABSORB

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

ABSORB EXTEND: BVS Safe Out to 3 Years

TCT 615: ABSORB EXTEND: An Interim Report on the 36-Month Clinical Outcomes from the First 250 Patients Enrolled

Rationale for Bioresorbable Vascular Scaffolds as a VP Shield: The PROSPECT ABSORB Trial

Innovation in Intervention: Perspectives from Industry

Bifurcation Strategies with the Absorb BVS Everolimus-Eluting Resorbable Scaffold: A Bench Study

TCT-36. One-year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis From the ABSORB Cohort B and the ABSO...

TCT-34. The appearance of jailed side branches post-procedure, at 6, 12, 24 and 36 months following implantation of bioresorbable vascular devices – Insights from the ABSORB...

TCT-32. First Report of the Four Year Clinical Results of The ABSORB Trial Evaluating the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Patients...

TCT-31. ABSORB EXTEND: An Interim Report on the 24-month Clinical Outcomes from the First 250 Patients Enrolled

2 Cases: Absorb in a Distal Left Main Bifurcation and a Non Left Main Bifurcation

Bioresorbable Scaffold Stands Ground Next to Current DES

ABSORB III and IV Trials Aim to Prove Superiority of BVS

Is ABSORB a Workhorse DES? Real-world Perspectives I

The ABSORB III trial: Design, Goals and Enrollment Status

Polylactic Acid Polymers: Chemistry and Structure in ABSORB 1.0 and 1.1

Micro-CT Observations with ABSORB: Insights into Bifurcation Technique

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content